ReutersThe U.S. government on Feb. 27 authorized Johnson & Johnson’s single-dose Covid-19 vaccine, enabling millions more Americans to be vaccinated in the coming weeks and setting the vaccine up for additional approvals around the world.
A panel of expert advisers to the U.S. Food and Drug Administration on Feb. 26 voted in favor of authorizing Johnson & Johnson’s Covid-19 vaccine for emergency use, bringing it an important step closer to a U.S. rollout.
Countries seeking their own COVID-19 vaccine doses are making deals with drug companies that threaten the supply for the global COVAX program for poor and middle-income countries, the World Health Organization said on Feb. 26.
The U.S. Food and Drug Administration on Feb. 25 approved storage and transportation of COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.
SARS-CoV-2 continues to mutate while spreading around the world – infecting more than 112.7 million people as of Feb. 25, according to the Johns Hopkins University of Medicine Covid-19 Dashboard – as companies such as Pfizer and Moderna evaluate boosters against new variants of the virus.
The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.
Many health experts believe that the Covid-19 vaccine candidate NVX-CoV237 from Novavax offers potential advantages over competitors including Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca-Oxford.
Johnson & Johnson’s one-dose Covid-19 vaccine appeared safe and effective in trials, the U.S. Food and Drug Administration said, paving the way for approval for emergency use as soon as Feb. 26.
Covid-19 vaccine makers told Congress on Feb. 23 that U.S. supplies should surge in the coming weeks due to manufacturing expansions and new vaccine authorizations.
Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push the Chinese fusion protein company’s Covid-19 vaccine into Phase II/III testing and production planning.
